Yes Re: eye catching news release. In the half year announcement buried on page 9, 'Patient responses to DMX-200 were measured using the Albumin Creatinine Ratio (ACR) reduction. Encouragingly, in the diabetic nephropathy sub-group of 10 patients, the average ACR was reduced by 35.6%. This is almost double the reduction in ACR seen in competing drug development programs by industry peers. ' IMO this could have been a headline item ! I am sure this will not be unnoticed anyway. Cheers
Yes Re: eye catching news release. In the half year announcement...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $25.68M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 38.0¢ | 36.0¢ | $870.7K | 2.355M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 107188 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 4504 | 1 |
View Market Depth
| Last trade - 16.10pm 04/12/2024 (20 minute delay) ? |
| DXB (ASX) Chart |